These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23913793)

  • 1. Healthcare costs associated with hepatocellular carcinoma and the value of care.
    Mantovani LG; Strazzabosco M
    Hepatology; 2013 Oct; 58(4):1213-4. PubMed ID: 23913793
    [No Abstract]   [Full Text] [Related]  

  • 2. Pricey pills for an even pricier problem.
    Kwan SW
    Cancer; 2016 Mar; 122(6):840-1. PubMed ID: 26716603
    [No Abstract]   [Full Text] [Related]  

  • 3. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
    Mantravadi S
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
    [No Abstract]   [Full Text] [Related]  

  • 4. Health care costs associated with hepatocellular carcinoma: a population-based study.
    Thein HH; Isaranuwatchai W; Campitelli MA; Feld JJ; Yoshida E; Sherman M; Hoch JS; Peacock S; Krahn MD; Earle CC
    Hepatology; 2013 Oct; 58(4):1375-84. PubMed ID: 23300063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
    Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
    Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular cancer care: cost is important but only one factor of disease burden.
    Kanwal F; El-Serag HB
    J Hepatol; 2009 Jan; 50(1):10-2. PubMed ID: 19019482
    [No Abstract]   [Full Text] [Related]  

  • 7. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis.
    Sangiovanni A; Manini MA; Iavarone M; Romeo R; Forzenigo LV; Fraquelli M; Massironi S; Della Corte C; Ronchi G; Rumi MG; Biondetti P; Colombo M
    Gut; 2010 May; 59(5):638-44. PubMed ID: 19951909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of illness associated with hepatocellular carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Shah S; Thompson D
    J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial Chemoembolization.
    Ahmed O; Patel M; Ward T; Sze DY; Telischak K; Kothary N; Hofmann LV
    J Vasc Interv Radiol; 2015 Dec; 26(12):1820-6.e1. PubMed ID: 26521766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
    Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From good to good deal: value-focused research.
    Duszak R
    J Vasc Interv Radiol; 2012 Mar; 23(3):315-6. PubMed ID: 22365290
    [No Abstract]   [Full Text] [Related]  

  • 12. Resource use and cost of hepatitis C-related care.
    Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain Analysis of Integrated Data to Reduce Cost Associated with Liver Disease.
    Motiwala T; Kite B; Regan K; Gascon GM; Payne PR
    Stud Health Technol Inform; 2015; 216():414-8. PubMed ID: 26262083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for hepatocellular carcinoma: does it work?
    Mallat DB; El-Serag HB
    Am J Gastroenterol; 2002 Oct; 97(10):2676-7. PubMed ID: 12385462
    [No Abstract]   [Full Text] [Related]  

  • 15. The lifetime cost of hepatocellular carcinoma : a claims data analysis from a medical centre in Taiwan.
    Lang HC; Wu JC; Yen SH; Lan CF; Wu SL
    Appl Health Econ Health Policy; 2008; 6(1):55-65. PubMed ID: 18774870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of liver cancer screening.
    Cucchetti A; Cescon M; Erroi V; Pinna AD
    Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):961-72. PubMed ID: 24182614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Burden of Hepatitis C Infection.
    Stepanova M; Younossi ZM
    Clin Liver Dis; 2017 Aug; 21(3):579-594. PubMed ID: 28689595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
    Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
    Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.
    Kuo MJ; Chen HH; Chen CL; Fann JC; Chen SL; Chiu SY; Lin YM; Liao CS; Chang HC; Lin YS; Yen AM
    World J Gastroenterol; 2016 Mar; 22(12):3460-70. PubMed ID: 27022228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for hepatocellular carcinoma: good enough but best yet to come.
    Amarapurkar D
    J Gastroenterol Hepatol; 2010 May; 25(5):845-6. PubMed ID: 20546433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.